Feature article: With ZETA on the Road to Net-Zero
Sustainability in the spotlight
Worldwide, businesses are recognizing their responsibilities and increasingly committing themselves to reducing and preventing harmful social and environmental impacts. The United Nations defined the Sustainable Development Goals (SDGs) in their 2030 Agenda, and thereby provided a global framework to achieve true sustainability.
Each of the 17 SDGs is essential and pharmaceutical companies can contribute considerably to many of them. In view of the climate emergency, developing a future-proof decarbonization strategy is becoming vital for every business or company.
Developing the roadmap to net-zero
In the development of decarbonization concepts, the challenge is to reconcile the expectations of external stakeholders ("top-down" perspective) with an internal ("bottom-up") perspective based on detailed technological assessments that show how much the carbon footprint can be reduced under the given technological and economic conditions.
A holistic view includes all relevant areas and business activities. For these analyses, ZETA evaluates current and future climate protection measures from a climate-specific and an economic perspective, using simulations and sensitivity analyses.
This results in structured cost-benefit calculations showing how much CO2 is saved by the implementation of the measures and what costs are entailed.
Elements of a corporate climate strategy
What are the elements of a corporate climate strategy that lead from mitigation of GHG emissions to climate neutrality? Very influential turnkeys in a net-zero roadmap are the energy efficiency of the company’s buildings, processes and vehicles, and a switch from fossil fuels to sustainable energy sources. Self-production – for example through photovoltaics – or procurement of green power is also a successful means of avoiding emissions.
Our expert is looking forward
to hearing from you!